Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate
Open Access
- 14 January 2016
- journal article
- forum
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 14 (1), 4
- https://doi.org/10.1186/s12916-016-0550-5
Abstract
The most prescribed medications in the world are statins, lipid modifiers that have been available for over 25 years and amongst the most investigated of all drug classes. With over a million patient years of trial data and publications in the most prestigious medical journals, it is remarkable that quite so much debate remains as to their place in healthcare. They have had a bittersweet passage, with vocal concerns over their possible risks, from suicide to cancer, and allegations that they do not work in women or the elderly, to statements that the whole published dataset, on over 200,000 patients consenting to enter trials, was fatally compromised by being industry-funded by and large. On the other side, there have been billions of dollars spent on generating their evidence base followed by promotion which has returned that investment many times over in profits, and a powerful scientific lobby that argue they are wonder drugs and that continued nihilism on their value risks patient lives. So who is right?This publication has 44 references indexed in Scilit:
- Primary Prevention of Cardiovascular Disease with a Mediterranean DietThe New England Journal of Medicine, 2013
- Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targetsVideosurgery and Other Miniinvasive Techniques, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Predictors of Nonadherence to Statins: A Systematic Review and Meta-AnalysisAnnals of Pharmacotherapy, 2010
- Review: Nutriceuticals as Antithrombotic AgentsCardiovascular Therapeutics, 2010
- The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsBMJ, 2009
- Relationship of Insulin Resistance and Related Metabolic Variables to Coronary Artery Disease: A Mathematical AnalysisDiabetes Care, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- Neutrophil Superoxide Anion Generation During Atorvastatin and Fluvastatin Therapy Used in Coronary Heart Disease Primary PreventionJournal of Cardiovascular Pharmacology, 2006
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002